194 related articles for article (PubMed ID: 33513396)
21. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
[TBL] [Abstract][Full Text] [Related]
22. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
[TBL] [Abstract][Full Text] [Related]
23. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
24. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.
Kumar P; Saini S; Khan S; Surendra Lele S; Prabhakar BS
Cell Immunol; 2019 May; 339():41-49. PubMed ID: 30482489
[TBL] [Abstract][Full Text] [Related]
25. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells.
Beauford SS; Kumari A; Garnett-Benson C
BMC Immunol; 2020 Apr; 21(1):18. PubMed ID: 32299365
[TBL] [Abstract][Full Text] [Related]
26. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
27. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
28. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
30. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.
Davidsson S; Carlsson J; Greenberg L; Wijkander J; Söderquist B; Erlandsson A
Microbiol Spectr; 2021 Dec; 9(3):e0149721. PubMed ID: 34937192
[TBL] [Abstract][Full Text] [Related]
31. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
33. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
34. M2 macrophages and regulatory T cells in lethal prostate cancer.
Erlandsson A; Carlsson J; Lundholm M; Fält A; Andersson SO; Andrén O; Davidsson S
Prostate; 2019 Mar; 79(4):363-369. PubMed ID: 30500076
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells in gastrointestinal tumors.
Raghavan S; Quiding-Järbrink M
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):489-501. PubMed ID: 21780896
[TBL] [Abstract][Full Text] [Related]
36. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells.
Huang H; Dawicki W; Zhang X; Town J; Gordon JR
J Immunol; 2010 Nov; 185(9):5003-10. PubMed ID: 20870943
[TBL] [Abstract][Full Text] [Related]
37. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
[TBL] [Abstract][Full Text] [Related]
38. FOXP3
Davidsson S; Andren O; Ohlson AL; Carlsson J; Andersson SO; Giunchi F; Rider JR; Fiorentino M
Prostate; 2018 Jan; 78(1):40-47. PubMed ID: 29105795
[TBL] [Abstract][Full Text] [Related]
39. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
40. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
